title: A Meta-analysis of Sequential Intravenous/Oral Moxifloxacin Monotherapy for Treatment of Skin and Skin Structure Infections.
abstract: Moxifloxacin is widely recognized for the treatment of bacterial infections of the respiratory tract such as community acquired pneumonia, acute bacterial sinusitis and acute exacerbations of chronic bronchitis. However, the use of moxifloxacin for skin infections is much valued in recent years. This study is to compare the clinical efficacy and safety of moxifloxacin monotherapy among adults with skin and skin structure infections. The meta-analysis of RCTs is conducted by searching Medline, Embase, Pubmed and the Cochrane Library. 6 RCTs, involving a total of 2608 patients, were included in the meta-analysis. English and Chinese language papers were reviewed. The results of the meta-analysis showed that the moxifloxacin monotherapy has similar clinical cure rate, bacteriological success rates and mortality compared with the control group. The drug-related adverse of moxifloxacin was significantly higher than that in the control group, although the overall incidence of adverse events, serious adverse events, and serious drug-related adverse events were similar between the compared treatment groups. Through this meta-analysis, we can draw a conclusion that moxifloxacin monotherapy has similar effectiveness and relative safety as other recommended antibiotics for the treatment of SSSIs. At the same time, it possesses the superior bacteria eradication rate. The once-daily dosing of moxifloxacin monotherapy may be a useful alternative for other recommended antibiotic therapy.
authors.affiliation: Department of Pharmacy, The First Affiliated Hospital of China Medical University, Shenyang, China.
authors.forename: Y
authors.initials: Y
authors.lastname: Chu
authors.affiliation: Department of Pharmacy, Dalian Medical University, Dalian, China.
authors.forename: J
authors.initials: J
authors.lastname: Qu
authors.affiliation: Department of Pharmacy, The First Affiliated Hospital of China Medical University, Shenyang, China.
authors.forename: L-Y
authors.initials: LY
authors.lastname: Qu
authors.affiliation: Department of Pharmacy, The First Affiliated Hospital of China Medical University, Shenyang, China.
authors.forename: Y-F
authors.initials: YF
authors.lastname: Luo
authors.affiliation: Department of Pharmacy, The First Affiliated Hospital of China Medical University, Shenyang, China.
authors.forename: M-Y
authors.initials: MY
authors.lastname: Jiang
mesh_terms: D061605:Administration, Intravenous; D000284:Administration, Oral; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use*; D024841:Fluoroquinolones / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D000077266:Moxifloxacin; D017192:Skin Diseases, Bacterial / Q000188:drug therapy*
chemical_list: D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones; D000077266:Moxifloxacin